SERB Specialty Pharmaceuticals is a global pharmaceutical group with essential products available in over 80 countries through a direct presence in Europe, US, the Middle East, Australia and our broad worldwide network of distributors. Our portfolio is focused on two key franchises: o CRITICAL CARE: • EMERGENCY CARE: wide range of lifesaving medical countermeasures and intensive care medicines. • SURGERY: drugs and devices for supportive care as well as diagnostic agents. o RARE DISEASES: • NEUROLOGY: treatments for rare and severe epileptic and neuromuscular conditions. • METABOLIC DISORDERS: medicines for paediatric inborn errors of metabolism. In 2020, we have strengthened our neurology and rare diseases portfolio with the strategic acquisition of Veriton Pharma (veritonpharma.com) in the UK. In 2021, we have enlarged our critical care medicines portfolio with the acquisition of BTG Specialty Pharmaceuticals (www.btgsp.com) and established our direct presence in US. We are committed to bringing further innovative solutions into the market by accelerating our acquisitions and enhancing our R&D pipeline. #proudtosavelives
View Top Employees from SERB PharmaceuticalsWebsite | http://www.serb.eu |
Revenue | $14 million |
Employees | 246 (126 on RocketReach) |
Founded | 1955 |
Technologies |
JavaScript,
HTML,
PHP
+23 more
(view full list)
|
Industry | Pharmaceuticals, Drug Manufacturing & Research, Biotechnology, Science and Engineering, Healthcare, Pharmaceutical, Health Care |
SIC | SIC Code 2834 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular SERB Pharmaceuticals employee's phone or email?
The SERB Pharmaceuticals annual revenue was $14 million in 2023.
126 people are employed at SERB Pharmaceuticals.
The NAICS codes for SERB Pharmaceuticals are [325, 32541, 3254, 32].
The SIC codes for SERB Pharmaceuticals are [2834, 283, 28].